作者
Thokozile R Malaba, Irene Nakatudde, Kenneth Kintu, Angela Colbers, Tao Chen, Helen Reynolds, Lucy Read, Jim Read, Lee-Ann Stemmet, Megan Mrubata, Kelly Byrne, Kay Seden, Adelline Twimukye, Helene Theunissen, Eva Maria Hodel, Justin Chiong, Nai-Chung Hu, David Burger, Duolao Wang, Josaphat Byamugisha, Yussif Alhassan, Sharon Bokako, Catriona Waitt, Miriam Taegtmeyer, Catherine Orrell, Mohammed Lamorde, Landon Myer, Saye Khoo, Marta Boffito, Polly Clayden, Tim Peto, Anton Pozniak, Graham Taylor, Andrew Kambugu, Tabitha Ayabo, Sabrina Bakeera Kitaka, Pauline Byakika-Kibwika, Daniel Kiiza, Isabella Kyohairwe, Eva Laker, Andrew Luswata, Johnson Magoola, Hamza Mayanja, Flavia Vivian Najujuma, Ritah Nakijoba, Diana Namuddu, Teopista Namuli, Peter Ntuyo, Annet Onzia, Emmanuel Sempijja, Jovia Tabwenda, Baluku William, Nina Abrahams, Phakamani Magano, Carmen Delport, Linda Hlwaya, Ushma Mehta, Dineo Molitsane, Jasantha Odayar, Sivuyile Tambula, Mbuviswa Tyam, Olga Venfolo, Joanna Allerton, Thozama Nkonyana, Sibongile Mqaba, Laura Else, Steve Potter, Anne Neary
发表日期
2022/8/1
期刊
The Lancet HIV
卷号
9
期号
8
页码范围
e534-e543
出版商
Elsevier
简介
Background
Late initiation of antiretrovirals in pregnancy is associated with increased risk of perinatal transmission and higher infant mortality. We report the final 72-week postpartum results for efficacy and safety of dolutegravir-based compared with efavirenz-based regimens in mothers and infants.
Methods
DolPHIN-2 was a randomised, open-label trial. Pregnant women in South Africa and Uganda aged at least 18 years, with untreated but confirmed HIV infection and an estimated gestation of at least 28 weeks, initiating antiretroviral therapy in third trimester were eligible for inclusion. Eligible women were randomly assigned (1:1) to receive either dolutegravir-based (50 mg dolutegravir, 300 mg tenofovir disoproxil fumarate, and either 200 mg emtricitabine in South Africa or 300 mg lamivudine in Uganda) or efavirenz-based (fixed dose combination 600 mg tenofovir disoproxil fumarate plus either emtricitabine in …
学术搜索中的文章
TR Malaba, I Nakatudde, K Kintu, A Colbers, T Chen… - The Lancet HIV, 2022